500 Per Cent Returns: Multibagger Specialty Chemicals & Pharma Stock Jumps 4.80 Per Cent; Earlier Company Acquired 2,09,100 Shares of Ishwari Healthcare Pvt Ltd
Today, shares of Sudarshan Pharma Industries Ltd plunged 4.80 per cent to an intraday high of Rs 369.95 per share from its previous closing of Rs 353 per share. The stock’s 52-week high is Rs 452.70 per share while its 52-week low is Rs 58.20 per share. The shares of the company saw a spurt in volume by more than 1.01 times on BSE.
The Board of Directors of the Company has approved the acquisition of 2,09,100 equity shares of Ishwari Healthcare Private Limited (Ishwari Healthcare), representing 51.00% of its paid-up equity share capital. Upon completion of the acquisition, Ishwari Healthcare will become a subsidiary of the Company. Ishwari Healthcare is a private limited company engaged in the business of producing, processing, preparing, treating, disinfecting, compounding, formulating, mixing, concentrating, packing, repacking, refining, adding, removing, purifying, preserving, grading, freezing, distillation, boiling, sterilizing, improving, extracting, buying, selling, reselling, trading, importing, exporting, bartering, transporting, storing, forwarding, distributing, disposing, developing, researching, discovering, manipulating, marketing, supplying, and dealing in various medical and surgical instruments, equipment, goods, products, instruments, apparatus, and devices related to all branches of medicine, surgery, and healthcare. The acquisition of Ishwari Healthcare aligns with the Company's strategic objectives and will strengthen its position in the healthcare industry.
Additionally, the Board of Directors of the company approved a sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up, subject to the approval of shareholders and such other approvals as may be required. The reason behind the split is to enhance the liquidity of the company’s share and to make it more affordable for small investors and also to broaden the company's investor base.
Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. Operating across diverse segments, including specialty chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply, SPIL caters to a wide range of institutions and healthcare organizations.
Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.
The company has a market cap of Rs 884 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of over 500 per cent from its 52-week low of Rs 58.20 per share. Investors should keep an eye on this micro-cap stock.